Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 6/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.63 |
| ▸ | F10 | P00742 | 13/20 | 0.55 |
| ▸ | F2 | P00734 | 4/20 | 0.55 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18040318 | 0.93 | F10 (0.61) | PDE4APDE4BPDE4CPDE4DF10 | |
| SCHEMBL18058755 | 0.93 | F10 (0.61) | PDE4APDE4BPDE4CPDE4DF10 | |
| SCHEMBL18040316 | 0.93 | F10 (0.61) | PDE4APDE4BPDE4CPDE4DF10 | |
| SCHEMBL20100169 | 0.90 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DF10 | |
| SCHEMBL16948138 | 0.90 | F10 (0.64) | PDE4APDE4BPDE4CPDE4DF10 | |
| SCHEMBL20100170 | 0.88 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DF10 | |
| SCHEMBL2000886 | 0.84 | F10 (0.63) | PDE4APDE4BPDE4CPDE4DF10 | |
| SCHEMBL5307046 | 0.84 | F10 (0.67) | PDE4APDE4BPDE4CPDE4DF10 | |
| SCHEMBL15731769 | 0.84 | F10 (0.67) | PDE4APDE4BPDE4CPDE4DF10 | |
| SCHEMBL18410362 | 0.83 | F10 (0.60) | PDE4APDE4BPDE4CPDE4DF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118737-A1 | DIMER IMPURITIES OF APIXABAN AND METHOD TO REMOVE THEM | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118737-A1 | DIMER IMPURITIES OF APIXABAN AND METHOD TO REMOVE THEM | F2, FGB, F8 | PDE4A 1016/4885PDE4B 826/4885PDE4C 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.